An attempt by the British Generic Manufacturers Association (BGMA) to get a seat at the negotiation table for the new Voluntary Scheme for Branded Medicines Pricing and Ac
Full FDA approval of Eisai and Biogen’s Alzheimer’s disease therapy Leqembi may have unlocked the door to a broader rollout of the drug and potentially blockbuster sales,
Novartis has suffered a defeat in its legal defence of chronic heart failure therapy Entresto, which accounted for around 11% of its revenues last year, but has vowed to t
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.